Oxaliplatin (Eloxatin) Plus Gemcitabine as First or Second-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2015
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 20 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 21 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Mar 2009 New trial record